The stock of Enzymotec Ltd (NASDAQ:ENZY) hit a new 52-week low and has $5.13 target or 10.00% below today’s $5.70 share price. The 9 months bearish chart indicates high risk for the $114.40 million company. The 1-year low was reported on Nov, 16 by Barchart.com. If the $5.13 price target is reached, the company will be worth $11.44M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 44,626 shares traded hands or 220.77% up from the average. Enzymotec Ltd (NASDAQ:ENZY) has declined 30.16% since April 14, 2016 and is downtrending. It has underperformed by 34.85% the S&P500.
Enzymotec Ltd (NASDAQ:ENZY) Ratings Coverage
Out of 3 analysts covering Enzymotec (NASDAQ:ENZY), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Enzymotec has been the topic of 4 analyst reports since August 13, 2015 according to StockzIntelligence Inc. On Thursday, August 13 the stock rating was upgraded by Wells Fargo to “Outperform”.
According to Zacks Investment Research, “Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel.”
More news for Enzymotec Ltd (NASDAQ:ENZY) were recently published by: Globenewswire.com, which released: “Enzymotec Ltd. Announces Departure of its CEO” on November 16, 2016. Reuters.com‘s article titled: “BRIEF-Enzymotec Ltd. announces departure of its CEO” and published on November 16, 2016 is yet another important article.
ENZY Company Profile
Enzymotec Ltd., incorporated on March 8, 1998, is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Firm operates in two divisions: Nutrition segment and VAYA Pharma segment. Both of the Company’s divisions offer a range of products that leverage its lipid-related offerings. The Company’s product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor’s supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company’s clinically-validated products include bio-functional lipid compounds designed to address dietary needs, medical disorders and common diseases. The Company’s technologies enable it to identify appropriate lipid-modifying enzymes and then improve the activity of these enzymes, as well as to enable their use in organic media. These enzymes are then utilized to restructure lipids found in natural sources, including krill, fish, vegetable sources and bovine milk.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.